STOCK TITAN

Maxcyte - MXCT STOCK NEWS

Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.

Overview

MaxCyte (MXCT) is a commercial cell engineering company that has established a strong reputation in the biopharma and cell therapy industries by harnessing its proprietary Flow Electroporation technology. This innovative platform facilitates high-efficiency cell transfection, enabling the complex engineering of a wide range of cell types. The company’s scalable and clinically validated systems support diverse applications from early-stage cell-based research to the commercialization of next-generation cell therapeutics.

Core Technology and Platforms

At the heart of MaxCyte’s operations is the Flow Electroporation technology, a sophisticated method designed to deliver genetic materials to cells with high precision. The technology minimizes cellular stress while maximizing transfection efficiency, which is crucial for both discovery research and clinical manufacturing. Complementing this is the ExPERT platform, a family of instruments and consumables that embody the latest advancements in electroporation technology. The ExPERT platform is engineered to support seamless scalability in complex cell engineering workflows, making it indispensable for developers working on cell and gene therapies.

Business Model and Revenue Streams

MaxCyte’s business model is built around a diversified revenue strategy. The company generates income through the sale of its cell engineering instruments, licensing its proprietary technologies, and through the continuous revenue stream provided by single-use processing assemblies and consumables. This model allows MaxCyte to support a wide array of partners—from academic research institutions to established biopharmaceutical companies. By licensing its technology to innovative companies, MaxCyte not only advances the state of cell-based research but also forms strategic partnerships that drive further adoption of its platforms.

Market Position and Industry Relevance

Operating at the intersection of biotechnology and medical device manufacturing, MaxCyte plays a vital role in enhancing the capabilities of cell and gene therapy development. Through its high-performance platforms, the company enables efficient, scalable, and reliable cell modification, which is essential in a field that continuously pushes the boundaries of therapeutic innovation. Its technology is employed across various stages of research and clinical development, making it a crucial enabler in the journey from laboratory discovery to commercial therapeutic applications.

Partnerships and Collaborative Developments

MaxCyte has established numerous pivotal partnerships with both clinical-stage enterprises and research organizations. Collaborations with companies developing engineered B cell medicines, allogeneic cell therapies, and advanced gene correction techniques underscore the versatility and broad application of its technology. Through these relationships, MaxCyte not only supports the technical and regulatory challenges inherent in therapeutic development but also benefits from a steady stream of research, clinical, and licensing revenues.

Technological Innovation and Support Services

Innovation remains at the core of MaxCyte’s strategy. The company continuously refines its platforms to enhance transfection efficiency and cell viability, addressing complex challenges in modern cell and gene therapies. Beyond the hardware, MaxCyte provides extensive scientific, technical, and regulatory expertise to its partners. This comprehensive support ensures that users of the platform can focus on the design and development of their therapies while relying on MaxCyte for reliable and validated cell-engineering solutions.

Competitive Landscape

Within the highly competitive bioscience and medical technology sectors, MaxCyte differentiates itself through its commitment to technological excellence and comprehensive support services. While several companies offer cell modification tools, MaxCyte’s combination of cutting-edge electroporation technology and robust intellectual property portfolio positions it uniquely in the market. Its emphasis on precision, scalability, and integrative support has allowed it to build strong, recurring revenue channels and foster lasting partnerships with innovators in the cell and gene therapy space.

Conclusion

In summary, MaxCyte is a crucial player in the transformation of cell-based research and therapeutics. Its pioneering Flow Electroporation technology and the versatile ExPERT platform not only propel advancements in cell engineering but also facilitate a wide range of pharmaceutical and academic research endeavors. By bridging key gaps in the therapeutic development process, MaxCyte continues to empower innovators and contribute to significant improvements in the field of biomedicine.

Rhea-AI Summary

MaxCyte, a leader in cell-engineering technology, plans to release its second-quarter 2022 financial results on August 10, 2022, post U.S. market close. Following the release, a conference call will be held at 4:30 p.m. ET to discuss the results. Investors can register for the call online, and a webcast will be available on MaxCyte's investor relations website. The company specializes in Flow Electroporation technology, supporting advancements in cell-based research and therapeutic discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
conferences earnings
-
Rhea-AI Summary

MaxCyte, Inc., (NASDAQ: MXCT) announced a strategic partnership with LG Chem on July 12, 2022, under which LG Chem will leverage MaxCyte's Flow Electroporation® technology and ExPERT™ platform to enhance its T-cell therapy candidates for solid tumors. This licensing agreement grants LG Chem clinical and commercial rights in exchange for licensing fees and revenue sharing. The partnership aims to bolster LG Chem's anti-cancer initiatives, particularly the CAR-T treatment currently in pre-clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
-
Rhea-AI Summary

On May 10, 2022, MaxCyte, Inc. (NASDAQ: MXCT) granted stock options for 73,700 shares to six newly hired employees as part of their 2021 Inducement Plan. The options have a ten-year term with an exercise price of $4.81 per share, equal to the stock's closing price on the grant date. These options will vest over four years, with 25% vesting after 12 months, subject to continued employment. MaxCyte focuses on cell-engineering technologies to support cell-based research and therapies, leveraging its proprietary Flow Electroporation platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
Rhea-AI Summary

MaxCyte reported a remarkable 78% increase in total revenue for Q1 2022, reaching $11.6 million, driven by a 48% growth in core revenues. Revenue from cell therapy customers rose by 57%, while drug discovery saw a 23% increase. Additionally, the company has raised its revenue guidance for 2022, expecting core business revenue growth of at least 25% and approximately $4 million in SPL Program-related revenue. Operating expenses increased, but the net loss reduced to $4.1 million from $7.1 million year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
-
Rhea-AI Summary

MaxCyte, a prominent commercial cell-engineering company, announced its participation in two upcoming investor conferences. The events include a presentation at the Bank of America 2022 Healthcare Conference on May 11 at 4:40 p.m. PT and a fireside chat at the William Blair 42nd Annual Growth Stock Conference on June 8 at 9:20 a.m. CT. Live and archived webcasts will be accessible on MaxCyte's investor relations website.

The company specializes in advanced cell-based research and has developed innovative platforms, such as the Flow Electroporation technology, to support cell therapy markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
conferences
-
Rhea-AI Summary

MaxCyte, Inc. (NASDAQ: MXCT) announced it will release its Q1 2022 financial results on May 9, 2022, after U.S. market close. A conference call with management is scheduled for 4:30 PM ET to discuss these results. The company specializes in cell-engineering technologies, including its proprietary Flow Electroporation® and ExPERT™ platforms, designed for the cell therapy market. This announcement sets the stage for financial insights and potential updates on growth in cell-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
conferences earnings
Rhea-AI Summary

MaxCyte, a leading cell-engineering company, announced on April 11, 2022, that it granted stock options for a total of 554,000 shares to newly hired employees, including 500,000 shares to Cenk Sumen, the new Chief Scientific Officer. The options, issued under the 2021 Inducement Plan, have a ten-year term with an exercise price of $5.67 per share, matching the stock's closing price on the grant date. Vested shares will occur over four years, contingent upon continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

MaxCyte, Inc. (NASDAQ: MXCT) announced the resignation of Amanda Murphy as Chief Financial Officer effective April 15, 2022. Ron Holtz, current Senior Vice President and Chief Accounting Officer, will serve as Interim CFO. MaxCyte expects first-quarter revenue to be at least $11.0 million, a significant increase from $6.5 million year-over-year. Additionally, core business revenue is anticipated to reach $9.0 million. Murphy will assist during the transition, while Sean Menarguez is promoted to Director, Investor Relations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

MaxCyte reported fourth quarter and full year 2021 results, showcasing record revenues of $10.2 million for Q4 and $33.9 million for the year, reflecting growth of 19% and 30%, respectively. Core business revenues surged by 37%, driven by a 43% increase from cell therapy customers. The company anticipates 2022 revenue growth of 22% to 25% over 2021, with SPL Program-related revenue projected at $4 million. Operating expenses rose to $48.4 million, leading to a net loss of $19.1 million for 2021. Cash reserves stood at $255 million as of year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
Rhea-AI Summary

MaxCyte has appointed Cenk Sumen, Ph.D., as the new Chief Scientific Officer (CSO), effective March 9, 2022. Dr. Sumen brings a wealth of experience in scientific innovation and technology development, having previously served as CTO at Stemson Therapeutics. MaxCyte is a pioneering cell-engineering company dedicated to advancing cell-based research and therapies with its Flow Electroporation® technology. CEO Doug Doerfler expressed enthusiasm for Dr. Sumen's strategic vision, which aims to enhance MaxCyte’s position in the growing cell therapy market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none

FAQ

What is the current stock price of Maxcyte (MXCT)?

The current stock price of Maxcyte (MXCT) is $2.45 as of April 4, 2025.

What is the market cap of Maxcyte (MXCT)?

The market cap of Maxcyte (MXCT) is approximately 262.4M.

What is MaxCyte's primary technology?

MaxCyte's core technology is its proprietary Flow Electroporation platform, which enables efficient and scalable cell engineering for research and therapeutic applications.

How does MaxCyte generate revenue?

The company generates revenue through the sale of its instruments, licensing of its proprietary technology, and the sale of single-use processing assemblies.

What industries benefit from MaxCyte's technology?

MaxCyte serves a broad range of sectors including biopharma, cell and gene therapy, and academic research by providing cutting-edge cell engineering tools.

How does the ExPERT platform support cell engineering?

The ExPERT platform offers a suite of instruments and consumables designed for high transfection efficiency, scalability, and precise cell modification, making it ideal for clinical and research applications.

What distinguishes MaxCyte from competitors?

MaxCyte differentiates itself with its clinically validated electroporation technology, robust intellectual property, and comprehensive support services that assist partners in navigating technical and regulatory challenges.

Who are the typical partners of MaxCyte?

MaxCyte collaborates with a diverse range of partners, including biotech companies developing cell therapies, academic research institutions, and clinical-stage organizations focusing on gene therapies.

What role does MaxCyte play in therapeutic development?

By providing advanced cell engineering platforms, MaxCyte is instrumental in advancing the discovery, development, and commercialization of next-generation cell-based therapeutics.

Why is scalable cell engineering important?

Scalable cell engineering is vital as it ensures that precise and efficient methods are available for modifying cells, which is crucial for the development and manufacturing of safe and effective therapies.
Maxcyte

Nasdaq:MXCT

MXCT Rankings

MXCT Stock Data

262.42M
99.48M
1.49%
74.25%
2.56%
Medical Devices
Services-commercial Physical & Biological Research
Link
United States
ROCKVILLE